Scott KitchenerMichael NissenPeter NasveldRemi ForratSutee YoksanJean LangJean François SaluzzoUniversity of QueenslandArmy Malaria InstituteSanofi Pasteur SAMahidol University2018-08-202018-08-202006-02-27Vaccine. Vol.24, No.9 (2006), 1238-12410264410X2-s2.0-32344443602https://repository.li.mahidol.ac.th/handle/123456789/23078We conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers. After one injection, all subjects reported systemic reactions consistent with a mild dengue-like syndrome. Seven volunteers developed dengue 3 viraemia after vaccination. All subjects developed a neutralizing antibody response against serotype 3 with partial response against other serotypes. The trial was stopped early (after 10 subjects enrolled) due to formulation issues, which were related to the dengue 3 vaccine component. Managing viral interference and balancing attenuation to produce acceptable tetravalent immunogenicity with minimal reactogenicity may be a recurring problem for future multivalent live vaccines. © 2005 Elsevier Ltd. All rights reserved.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineVeterinaryArticleSCOPUS10.1016/j.vaccine.2005.09.029